Expert Interview
A second look at the developing BTK inhibitor landscape for CLL and SLL with a primary focus on the the ASH updates from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo.
Ticker(s): BGNE, AZN, NRIXInstitution: Mount Sinai
- Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai.
- Currently manages ~250 patients with CLL and SLL and 70 patients with Hodgkin Lymphoma.
- Research areas of focus include Lymphoma immunotherapy and B-cell receptor signaling inhibitors (e.g. PI3K, mTOR, BTK)
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 05, 2025
- Call Time
- 05:00 PM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
